進行腎細胞がんの疫学予測(~2028)

◆英語タイトル:Advanced Renal Cell Carcinoma Epidemiology Forecast-2028
◆商品コード:DATA00109003
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2019年12月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD3,250 ⇒換算¥370,500見積依頼/購入/質問フォーム
Global Site License(法人閲覧用)USD9,750 ⇒換算¥1,111,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Advanced Renal Cell Carcinoma Epidemiology Forecast-2028
DelveInsight’s ‘Advanced Renal Cell Carcinoma Epidemiology Forecast—2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Advanced Renal Cell Carcinoma in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
• China

Study Period: 2017–2028
Advanced Renal Cell Carcinoma Epidemiology

According to the National Organization of Rare Disorders (NORD), renal cell carcinoma accounts for approximately 30,000 new cases of kidney malignancies per year in the United States. It is more common in males than in females (ratio of 2–3:1) and in persons with a history of smoking.

Renal cell carcinomas (RCC) are primary malignant adenocarcinomas derived from the renal tubular epithelium and are the most common malignant renal tumor. They usually occur in 50–70 year old patients and macroscopic hematuria occurs in 60% of the cases.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Advanced Renal Cell Carcinoma in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028 for the following aspects:
• Diagnosed Incident Cases of Renal Cell Carcinoma (RCC)
• Gender-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC)
• Subtype-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC)
• Stage-specific Diagnosed Incident Cases of RCC
• Total Cases of Advanced/Metastatic RCC
According to DelveInsight, the total diagnosed incident cases of Advanced Renal Cell Carcinoma in the G8 countries were 69,429 in 2017. In case of total RCC patients in the United States, the diagnosed incident cases were 53,405 in 2017.

Report Scope

• The report covers the detailed overview of Advanced Renal Cell Carcinoma explaining its causes, symptoms, and classification, pathophysiology, diagnosis and treatment patterns.
• The report provides insight about the historical and forecasted patient pool for G8 countries covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan and China.
• The report assesses the disease risk and burden and highlights the unmet needs of Advanced Renal Cell Carcinoma.
• The report helps to recognize the growth opportunities in the G8 countries with respect to the patient population.
• The report provides the segmentation of the disease epidemiology by type-specific cases and severity specific cases of Advanced Renal Cell Carcinoma in the G8 countries.

Key strengths

• 10-Year Forecast of Advanced Renal Cell Carcinoma epidemiology
• G8 countries Coverage
• Total Incident Cases of Advanced Renal Cell Carcinoma
• Incident Cases according to segmentation

Key assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Note: We understand the needs of the rapidly changing market and DelveInsight’s is helping the clients by providing them with the most up to date Report. It usually takes 5–7 days.

【レポートの目次】

1. Key Insights
2. Disease Background and Overview: Advanced Renal Cell carcinoma
2.1. Introduction
2.2. Histologic Subtypes and Related Molecular Pathways
2.2.1. Clear Cell Renal Cell Carcinoma
2.2.2. Non-clear-cell renal cell carcinomas
2.3. Biology and pathology of renal cell carcinoma
2.4. Pathophysiology
2.5. Risk Factors of Advanced Renal Cell Carcinoma
2.6. Mechanisms of Renal Cell Carcinoma
2.6.1. Genes and pathways
2.6.2. Tumor heterogeneity and cancer evolution
2.6.3. Immune infiltration and the tumor microenvironment
2.7. Staging of renal cell carcinoma
2.7.1. TNM Staging
2.7.2. Composite grading systems for renal carcinoma
2.7.3. Fuhrman Nuclear Grade
2.8. Genetic Pathology of renal cell carcinoma
2.8.1. Von Hippel–Lindau gene
2.8.2. Protein polybromo-1 gene
2.8.3. BRCA1-associated protein-1
2.8.4. The mTOR pathway
2.9. Epigenetics of RCC
2.10. Tumor Behavior and Prognostic Molecular Markers
2.11. Metabolic pathways and targets in renal cell carcinoma
2.11.1. The Glutaminase Pathway
2.11.2. Other metabolic pathways and targets
2.12. Role of the Immune System in Renal Cell Carcinoma
2.12.1. The programmed death-1 receptor (PD-1 receptor) pathway
2.12.2. Interaction between Angiogenesis and the Anti-Tumor Immune Response
2.13. Biomarkers
2.13.1. Molecular biomarkers
2.13.2. Inflammatory Proteins
2.13.3. Molecular Markers in Urine
2.14. Diagnosis
2.14.1. Size, Extent of Invasion Outside of the Kidney
2.14.2. Genomic implications
2.14.3. Histopathological confirmation
2.14.4. Radiologic Evaluation
2.14.5. Screening and Imaging
2.14.6. Preoperative Evaluation
2.15. Diagnostic Guidelines
2.15.1. European Association of Urology Guidelines on Renal Cell Carcinoma: 2019
2.15.2. Renal Mass and Localized Renal Cancer: AUA Guideline (2017)
2.15.3. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis
2.16. Nutshell: Advanced Renal Cell Carcinoma
3. Epidemiology and Patient Population
3.1. Key Findings
3.2. G8 Countries Total Diagnosed Incident Patient Population of Advanced Renal Cell Carcinoma (RCC)
4. Country Wise-Epidemiology of Advanced Renal Cell Carcinoma (RCC)
4.1. United States
4.1.1. Assumptions and Rationale
4.1.2. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United States
4.1.3. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United States
4.1.4. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United States
4.1.5. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United States
4.1.6. Advanced/Metastatic RCC Total Cases in the United States
4.2. EU5 Countries
4.2.1. Assumptions and Rationale
4.3. Germany
4.3.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Germany
4.3.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Germany
4.3.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Germany
4.3.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Germany
4.3.5. Advanced/Metastatic RCC Total Cases in Germany
4.4. France
4.4.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in France
4.4.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in France
4.4.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in France
4.4.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in France
4.4.5. Advanced/Metastatic RCC Total Cases in France
4.5. Italy
4.5.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Italy
4.5.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Italy
4.5.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Italy
4.5.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Italy
4.5.5. Advanced/Metastatic RCC Total Cases in Italy
4.6. Spain
4.6.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Spain
4.6.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Spain
4.6.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Spain
4.6.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Spain
4.6.5. Advanced/Metastatic RCC Total Cases in Spain
4.7. United Kingdom
4.7.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United Kingdom
4.7.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United Kingdom
4.7.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United Kingdom
4.7.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United Kingdom
4.7.5. Advanced/Metastatic RCC Total Cases in the United Kingdom
4.8. Japan
4.8.1. Assumptions and Rationale
4.8.2. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Japan
4.8.3. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Japan
4.8.4. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Japan
4.8.5. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Japan
4.8.6. Advanced/Metastatic RCC Total Cases in Japan
4.9. China
4.9.1. Assumptions and Rationale
4.9.2. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in China
4.9.3. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in China
4.9.4. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in China
4.9.5. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in China
4.9.6. Advanced/Metastatic RCC Total Cases in China
5. Appendix
5.1. Report Methodology
6. DelveInsight Capabilities
7. Disclaimer
8. About DelveInsight
Table 1 Types of Non-clear-cell renal cell carcinomas
Table 2 Histological features of papillary urothelial lesions
Table 3 Guidelines for the diagnosis of Renal Cell Carcinoma
Table 4 Total Diagnosed Incident Population of Advanced Renal Cell Carcinoma (RCC) in the G8 Countries (2017–2028)
Table 5 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United States (2017–2028)
Table 6 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United States (2017–2028)
Table 7 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United States (2017–2028)
Table 8 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United States (2017–2028)
Table 9 Advanced/Metastatic RCC Total Cases in the United States (2017–2028)
Table 10 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Germany (2017–2028)
Table 11 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Germany (2017–2028)
Table 12 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Germany (2017–2028)
Table 13 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Germany (2017–2028)
Table 14 Advanced/Metastatic RCC Total Cases in Germany (2017–2028)
Table 15 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in France (2017–2028)
Table 16 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in France (2017–2028)
Table 17 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in France (2017–2028)
Table 18 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in France (2017–2028)
Table 19 Advanced/Metastatic RCC Total Cases in France (2017–2028)
Table 20 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Italy (2017–2028)
Table 21 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Italy (2017–2028)
Table 22 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Italy (2017–2028)
Table 23 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Italy (2017–2028)
Table 24 Advanced/Metastatic RCC Total Cases in Italy (2017–2028)
Table 25 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Spain (2017–2028)
Table 26 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Spain (2017–2028)
Table 27 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Spain (2017–2028)
Table 28 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Spain (2017–2028)
Table 29 Advanced/Metastatic RCC Total Cases in Spain (2017–2028)
Table 30 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United Kingdom (2017–2028)
Table 31 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United Kingdom (2017–2028)
Table 32 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United Kingdom(2017–2028)
Table 33 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United Kingdom (2017–2028)
Table 34 Advanced/Metastatic RCC Total Cases in the United Kingdom (2017–2028)
Table 35 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Japan (2017–2028)
Table 36 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Japan (2017–2028)
Table 37 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Japan (2017–2028)
Table 38 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Japan (2017–2028)
Table 39 Advanced/Metastatic RCC Total Cases in Japan (2017–2028)
Table 40 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in China (2017–2028)
Table 41 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in China (2017–2028)
Table 42 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in China (2017–2028)
Table 43 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in China (2017–2028)
Table 44 Advanced/Metastatic RCC Total Cases in China (2017–2028)
Figure 1 VHL inactivation in ccRCC and its implication in targeted therapy
Figure 2 Cancer evolution and tumor heterogeneity in ccRCC
Figure 3 Von Hippel–Lindau gene (HIF1A and HIF2A are hydroxylated on proline residues and bind the pVHL, resulting in polyubiquitination of HIFA)
Figure 4 The mTOR–PI3K pathway.
Figure 5 Distinct signaling pathways involved in programmed death 1 (PD-1)/PD-L1 interaction in the tumor microenvironment
Figure 6 Cellular and molecular components of the tumor ecosystem that shape the tumor angiogenic landscape.
Figure 7 Stages of kidney cancer and recommended treatments
Figure 8 Total Diagnosed Incident Patient Population of Advanced Renal Cell Carcinoma (RCC) in the G8 Countries (2017–2028)
Figure 9 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United States (2017–2028)
Figure 10 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United States (2017–2028)
Figure 11 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United States (2017–2028)
Figure 12 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United States (2017–2028)
Figure 13 Advanced/Metastatic RCC Total Cases in the United States (2017–2028)
Figure 14 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Germany (2017–2028)
Figure 15 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Germany (2017–2028)
Figure 16 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Germany (2017–2028)
Figure 17 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Germany (2017–2028)
Figure 18 Advanced/Metastatic RCC Total Cases in Germany (2017–2028)
Figure 19 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in France (2017–2028)
Figure 20 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in France (2017–2028)
Figure 21 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in France (2017–2028)
Figure 22 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in France (2017–2028)
Figure 23 Advanced/Metastatic RCC Total Cases in France (2017–2028)
Figure 24 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Italy (2017–2028)
Figure 25 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Italy (2017–2028)
Figure 26 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Italy (2017–2028)
Figure 27 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Italy (2017–2028)
Figure 28 Advanced/Metastatic RCC Total Cases in Italy (2017–2028)
Figure 29 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Spain (2017–2028)
Figure 30 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Spain (2017–2028)
Figure 31 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Spain (2017–2028)
Figure 32 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Spain (2017–2028)
Figure 33 Advanced/Metastatic RCC Total Cases in Spain (2017–2028)
Figure 34 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United Kingdom (2017–2028)
Figure 35 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United Kingdom (2017–2028)
Figure 36 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United Kingdom(2017–2028)
Figure 37 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United Kingdom (2017–2028)
Figure 38 Advanced/Metastatic RCC Total Cases in the United Kingdom (2017–2028)
Figure 39 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Japan (2017–2028)
Figure 40 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Japan (2017–2028)
Figure 41 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Japan (2017–2028)
Figure 42 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Japan (2017–2028)
Figure 43 Advanced/Metastatic RCC Total Cases in Japan (2017–2028)
Figure 44 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in China (2017–2028)
Figure 45 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in China (2017–2028)
Figure 46 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in China (2017–2028)
Figure 47 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in China (2017–2028)
Figure 48 Advanced/Metastatic RCC Total Cases in China (2017–2028)



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[進行腎細胞がんの疫学予測(~2028)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆